 VolitionRx NYSE-A:VNRX Limited has announced a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of neutrophil extracellular traps NETs in cancer patients with sepsis. The diagnostics and monitoring company said the trial will use Volitions Nu.Q NETs test for the study, which was Conformitè Europëenne CE marked earlier this year for the detection and evaluation of NETosis. 